Argenx seen down after halt to eye disease studies for efgartigimod
15/12/2025 07:50
** Shares in argenxARGX.BR are seen down 3-7% by traders after the Dutch biopharma company discontinued a phase 3 trial for thyroid eye disease (TED) treatment ** Argenx said on Monday it discontinued the efgartigimod TED studies after a futility evaluation by an independent data monitoring committee ** The efgartigimod antibody fragment is associated with ArgenX's key drug Vyvgart ** J.P. Morgan says it still expects argenx to continue to offer a strong growth profile, with four additional registration trials expected in 2026 ** As of Friday's closing, shares in argenx are up 26% YTD (Reporting by Alessandro Parodi) ((Alessandro.Parodi@thomsonreuters.com;))
Recent news on argenx SE
See all newsArgenx falls after Vyvgart trial update on myositis drug, brokers remain positive
Brief: ArgenX Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’S Disease
Brief: argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Brief: Argenx Q1 Total Operating Income USD 1.313 Bln
Netherlands' Argenx Q1 net sales rise 63%, profit more than doubles